CDC Updates COVID-19 and Chickenpox Vaccination Guidelines; Court Rules Against Novo Nordisk on IRA Drug Pricing Challenge

The Centers for Disease Control and Prevention (CDC) has introduced updates to its vaccination guidelines, adopting a more individualized approach to COVID-19 immunization. Additionally, the agency revised its recommendations for chickenpox vaccinations in toddlers. Meanwhile, new research highlights potential complications with PET-CT imaging results linked to GLP-1 therapies, and the Third Circuit Court has ruled against Novo Nordisk in its challenge to provisions of the Inflation Reduction Act (IRA).

The CDC’s updated COVID-19 vaccination guidance emphasizes tailoring recommendations based on individual health conditions and risk factors rather than applying a universal approach. For chickenpox, the agency adjusted its guidelines for toddlers, though specific details of these changes were not disclosed. In separate developments, researchers have identified that GLP-1 receptor agonists—commonly used in diabetes and weight-loss treatments—may interfere with PET-CT imaging accuracy by affecting glucose metabolism patterns. Lastly, the Third Circuit Court rejected Novo Nordisk’s legal challenge to provisions within the IRA aimed at controlling drug prices. The court’s decision marks a significant development in ongoing disputes between pharmaceutical companies and federal regulations targeting medication affordability.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: October 10, 2025

Author

Mark Chiang